{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"The outcome measure \"Primary Outcome: Selumetininb AUC0-12₂ Derived After Single Dose Administration\" is one of two co-primary endpoints. The second co-primary endpoint - \"Adverse Events Graded by CTCAE Version 5.0\" - is still ongoing. As a result, the study has not yet reached the Primary Completion Date at the time these results were submitted. Full results, including data for the second co-primary endpoint, will be submitted upon completion of the study."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca","phone":"1-877-240-9479","title":"Global Clinical Lead"}}